P26
Libevitug treatment in chronic hepatitis D: virologic, biochemical, and biomarker improvements through 48 weeks
S.S. Hamid, Y. Xie, Z. Abbas, C. Wu, X.Z. Wang, A.Majeed, L. Zhang, X.N. Wu, O. Afzal, S.Nazir, H. Zhou, J. Wu, F. Guo, Z.G. Wang, Q. Xu, X. Zhou, L.F. Zou, Y.H. Qi, G.Y. Li, P. Chen, J.Y. Wen, Z.M. Zhou, X.P. Chen, B.Ye, Y. Zhang, B.Chen, J.H. Shui, W.H.
P27
Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial
R. Taylor, T. Asselah, O. Etzion, S. Hamid, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, T. Petrivna, L. Gheorghe, G. Stancu, N. Voronkova, N. Bursuko-va, S. Aleman, J. Feld, R. Gish, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. H
P28
Post-treatment response following 48 weeks of lonafarnib therapy: analysis of 24-week follow-up in the phase 3 D-LIVR trial in chronic hepatitis delta
S. Hamid, O. Etzion, T. Asselah, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, T. Petrivna, L. Gheorghe, G. Stancu, N. Voronkova, N. Bursukova, S. Aleman, J. Feld, R. Taylor, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C.
P29
Clinical significance of ALT dynamics following lonafarnib treatment cessation in the phase 3 D-LIVR trial
O. Etzion, S. Hamid, T. Asselah, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, H. Bonkovsky, J. Lewis, J. Ahmad, S. Aleman, J. Feld, R. Taylor, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C. Yurdaydin, X. Hua, J. Glenn
P30
Brelovitug Monotherapy for the Treatment of Chronic Hepatitis D: Primary 24 Week Efficacy and Safety Results from the AZURE-1 Phase 2b Study
T. Kushner, D. Yardeni, M. Dobryanska, A. Jucov, D. Dieterich, J. Feld, M. Butsashvili, E. Dolmazashvili, D. Gerov, T. Khuchua, T. Saadi, D. Kaplan, J. Park, D. Pavlov, M. Radicheva, C. Coffin, E. Gane, S. Poulin, I. Jacobson, M. Levy, M. Sulkowski, N. Te
P31
Brelovitug Monotherapy for the Treatment of Chronic Hepatitis D: Primary 24-Week Efficacy and Safety Results in Patients with Baseline Platelet Counts <100,000/µL from the AZURE-1 Phase 2b Study
D. Dieterich, D. Yardeni, T. Kushner, M. Dobryanska, A. Jucov, J. Feld, M. Butsashvili, E. Dolmazashvili, D. Gerov, T. Khuchua, T. Saadi, D. Kaplan, J. Park, D. Pavlov, M. Radicheva, C. Coffin, E. Gane, S. Poulin, I. Jacobson, M. Levy, M. Sulkowski, N. Terrault, K. Doucette, N. Reau, S. Strasser, T. Tanaka, A. Duzik, S. Tan, S. Naim, W. Garner, D. Weerasinghe, M. Bosse, N. Shulman, C. Yurdaydin, S. Hamid
P33
Mathematical modeling reveals mechanisms of response to pegylated interferon-alpha in chronic hepatitis D: Insights from the D-LIVR Study
A. Omesi, L. Shekhtman, A. Mhlanga, T. Heller, C. Koh, J. Glenn, T. Asselah, S. Hamid, D. Yardeni, S.J. Cotler, H. Dahari, O. Etzion
